Willfact (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
288 | 自己免疫性後天性凝固因子欠乏症[自己免疫性出血病XIII (~2017.3)] | 3 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03613584 (ClinicalTrials.gov) | April 16, 2018 | 22/3/2018 | Von Willebrand Factor Concentrate During ECMO Support | A Double-blind, Placebo-controlled Pilot Trial to Investigate the Administration of Von Willebrand Factor Concentrate (Willfact®, LFB France) in Adult Patients During Extracorporeal Membrane Oxygenation | Acquired Von Willebrand Disease | Drug: Von Willebrand Factor;Drug: Saline Solution | Tirol Kiniken GmbH | LFB BIOMEDICAMENTS | Active, not recruiting | 18 Years | N/A | All | 68 | Phase 2 | Austria |
2 | EUCTR2017-003036-37-AT (EUCTR) | 27/10/2017 | 14/09/2017 | The influence of the medication Willfact on the blood loss of patient during the use of a heart-lung machine | A double-blind, placebo-controlled pilot trial to investigate the administration of von Willebrand factor concentrate (Willfact®, LFB France) in adult patients during extracorporeal membrane oxygenation - Von Willebrand factor concentrate during ECMO support | Von Willebrand Disease (VWD) MedDRA version: 20.0;Level: PT;Classification code 10069495;Term: Acquired Von Willebrand's disease;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Trade Name: Willfact Product Name: Willfact INN or Proposed INN: von Willebrand Faktor Other descriptive name: VON WILLEBRAND FACTOR Trade Name: Physiologische Kochsalzlösung Fresenius - Infusionslösung Product Name: Physiologische Kochsalzlösung Fresenius - Infusionslösung INN or Proposed INN: Natriumchlorid 0,9 % Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9% Trade Name: Willfact Product Name: Willfact INN or Proposed INN: von Willebrand Faktor Other descriptive name: VON WILLEBRAND FACTOR Trade Name: Willfact Product Name: Willfact INN or Proposed INN: von Willebrand Faktor Other descriptive name: VON WILLEBRAND FACTOR | Tirol Kliniken GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 68 | Phase 2 | Austria | ||
3 | EUCTR2016-000789-53-AT (EUCTR) | 09/03/2017 | 17/10/2016 | The influence of the medication Willfact on the blood loss of patient during the use of a heart-lung machine | A pilot trial to investigate the administration of von Willebrand factor concentrate (Willfact®, LFB France) in adult patients during extracorporeal membrane oxygenation - Willfact during ECMO | Von Willebrand Disease (VWD) MedDRA version: 19.1;Level: PT;Classification code 10069495;Term: Acquired Von Willebrand's disease;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Trade Name: Willfact Product Name: Willfact INN or Proposed INN: von Willebrand Faktor Other descriptive name: VON WILLEBRAND FACTOR Trade Name: Physiologische Kochsalzlösung Fresenius - Infusionslösung Product Name: Physiologische Kochsalzlösung Fresenius - Infusionslösung INN or Proposed INN: Natriumchlorid 0,9 % Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9% Trade Name: Willfact Product Name: Willfact INN or Proposed INN: von Willebrand Faktor Other descriptive name: VON WILLEBRAND FACTOR Trade Name: Willfact Product Name: Willfact INN or Proposed INN: von Willebrand Faktor Other descriptive name: VON WILLEBRAND FACTOR | Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | Austria |